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Abstract
In this randomized clinical trial, the clinical and mycological efﬁcacy of Photodynamic Therapy (PDT) was compared with that of topical
antifungal therapy for the treatment of denture stomatitis (DS) and the prevalence of Candida species was identiﬁed. Patients were ran-
domly assigned to one of two groups (n = 20 each); in the nystatin (NYT) group patients received topical treatment with nystatin
(100 000 IU) four times daily for 15 days and in the PDT group the denture and palate of patients were sprayed with 500 mg/L of
Photogem, and after 30 min of incubation, were illuminated by light emitting-diode light at 455 nm (37.5 and 122 J/cm2, respectively)
three times a week for 15 days. Mycological cultures taken from dentures and palates and standard photographs of the palates were
taken at baseline (day 0), at the end of the treatment (day 15) and at the follow-up time intervals (days 30, 60 and 90). Colonies were
quantiﬁed (CFU/mL) and identiﬁed by biochemical tests. Data were analysed by Fisher’s exact test, analysis of variance and Tukey tests
and j test (a = 0.05). Both treatments signiﬁcantly reduced the CFU/mL at the end of the treatments and on day 30 of the follow-up
period (p <0.05). The NYT and PDT groups showed clinical success rates of 53% and 45%, respectively. Candida albicans was the most
prevalent species identiﬁed. PDT was as effective as topical nystatin in the treatment of DS.
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Introduction
Denture stomatitis (DS) is the most common form of oral
candidiasis with an overall incidence of 11–65% in complete
denture wearers. This recurring disease is characterized by
different degrees of inﬂammation of the mucosa under the
maxillary denture, ranging from petechiae to generalized
inﬂammation with papillary hyperplasia [1]. The aetiology of
this problem is multifactorial: decreased salivary ﬂow, medi-
cation, endocrinopathies, immunosuppression, metabolic and
nutritional factors, smoking, increased age of denture, den-
ture trauma, continuous denture wearing, and poor denture
hygiene have been implicated [2]. Nonetheless, the denture–
palatal interface offers a unique ecological niche for microor-
ganism colonization because of the relatively anaerobic and
acidic environment favouring yeast proliferation without any
other predisposing factor present.
Candida albicans is the yeast species most frequently iso-
lated in signiﬁcant quantities from subjects with DS [1–8].
This oral fungal pathogen is able to grow in a variety of mor-
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phological forms, ranging from blastospores to hyphae. The
ﬁlamentous growth can promote tissue penetration during
the early stages of infection [9]. Moreover, on soft and hard
surfaces within the oral cavity, C. albicans grows as a bioﬁlm,
which consists of a complex community of cells embedded in
a matrix of extracellular polysaccharide. When cells exist in
a bioﬁlm they exhibit phenotypic properties that are distinct
from those of planktonic cells and they have increased resis-
tance to antimicrobial agents [10]. Although C. albicans is the
most prevalent and virulent species of the genus Candida,
other non-C. albicans species are often isolated from acrylic
surfaces and the palatal mucosa, such as: C. glabrata, C. tropi-
calis, C. parapsilosis, C. pseudotropicalis, C. krusei and C. guillier-
mondii. The emergence of other Candida species is important
because they may exhibit higher denture surface adherence,
and species such as C. glabrata, C. krusei and C. lusitaniae
show inherent resistance or intrinsic reduced susceptibility
to antifungal agents [11].
Antifungal agents are commonly used to treat DS, but
improvement in denture hygiene, discontinuation of noctur-
nal denture wearing, and eventually relining or replacing the
denture are also required. Topical agents such as nystatin
and miconazole have been used effectively [12,13]. However,
the diluent effect of saliva and the cleansing action of the
oral musculature tend to reduce the concentration of these
agents to sub-therapeutic levels. Hence, treatment regimens
tend to be prolonged and recurrence rates are high.
Systemic antifungal agents such as amphotericin B and
ﬂuconazole are also effective, but they do not eradicate the
microorganisms that colonize the denture [12]. Nonetheless,
the major problem associated with the prolonged or recur-
rent use of antifungal drugs is the development of resistant
species [9,11,13].
This makes it necessary to seek new therapeutic
approaches. A promising modality is Photodynamic Therapy
(PDT), which uses a photosensitizing agent and light of
appropriate wavelength. The interaction between the photo-
sensitizer and light in the presence of oxygen produces reac-
tive species, such as singlet oxygen and free radicals, which
cause cell damage and death [14,15]. As a consequence of
these non-speciﬁc oxidizing agents, organisms resistant to
conventional antifungal agents could be successfully killed by
PDT, and it seems unlikely that they will develop resistance
to such a therapy. PDT is effective against oral species and
may not promote damage to host cells and tissues [16,17].
Investigations have shown that Candida spp. are suscepti-
ble to photoinactivation [14–16,18], including resistant
strains [19,20]. Previous studies have shown that PDT is
effective in reducing C. albicans counts in a murine model of
oral candidiasis [16] and for denture disinfection [21,22]
when a porphyrin was associated with light-emitting diode
(LED) light. In a recent case report, ﬁve patients with
clinical and microbiological diagnoses of DS were success-
fully treated with PDT [5]. Nonetheless, the clinical effec-
tiveness of PDT in comparison with conventional antifungal
therapy in the treatment of DS is not yet known. Hence,
the aims of the present randomized clinical trial were to
compare the efﬁcacy of PDT with that of topical nystatin in
the treatment of DS and to identify the prevalence of Can-
dida species.
Materials and Methods
Study design
This was a two group, parallel, randomized clinical trial com-
paring the effectiveness of PDT and nystatin in the treatment
of patients with DS. The procedures carried out in the study
were in compliance with the criteria of Resolution 196/96 of
the Brazilian Health Ministry, which regulates research
involving human subjects. This research was conducted in
accordance with the Declaration of Helsinki, and the proto-
col of the entire project was approved by the Ethics Com-
mittee of the Araraquara Dental School (39/2005—1308.
0.199.000-05 SISNEP). All participants were made aware of
the objectives of the study and of the probable risks and
beneﬁts. All subjects voluntarily entered the study and signed
an informed consent form before their enrolment.
Participants and randomization
Edentulous denture-wearing patients attending the Araraqu-
ara Dental School for prosthetic treatment were examined
for clinical evidence of DS. The exclusion criteria were
based on the medical history of each individual, which was
checked for factors known to affect carriage of Candida spp.,
such as diabetes, anaemia, immunosuppression and cancer
therapy (radiotherapy or chemotherapy). Similarly, individu-
als who had received in the past 3 months or who were
currently receiving treatment with antibiotics, antifungal
agents or steroids were excluded. A total of 40 voluntary
patients were selected for inclusion in the present study.
Medical and dental histories of the patients were recorded,
and comprehensive oral examinations were performed by
the same investigator. DS was classiﬁed according to the cri-
teria proposed by Newton [23]. To create groups of
patients that were similar with regard to baseline character-
istics that could inﬂuence prognosis other than the treat-
ment being considered, namely risk factors, a stratiﬁed
randomization was used. The following risk factors were
considered in this study: age of the dentures, smoking habits,
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medication use, denture hygiene habits and nocturnal wear-
ing of dentures.
Photosensitizer and light sources
The photosensitizer used in this study was a haematoporphy-
rin derivative (Photogem, Photogem LLC Co, Moscow,
Russia). Solutions of 500 mg/L Photogem were prepared by
dissolving the powder in sterile saline immediately before
use (pH 6.6) [5,16]. This solution was stored in a sterile
spray bottle and kept in the dark. The absorption properties
of Photogem were investigated spectrophotometrically in sal-
ine solution (Fig. 1). Absorption spectra were obtained using
a UV-visible spectrophotometer (Varian Cary 50 Bio UV,
McKinley Scientiﬁc, Sparta, NJ, USA).
Two LEDs (LXHL-PR09; Luxeon III Emitter, Lumileds
Lighting, San Jose, CA, USA) devices were designed by Insti-
tuto de Fı´sica de Sa˜o Carlos (University of Sa˜o Paulo, Sa˜o
Carlos, SP, Brazil) especially for this investigation. They cov-
ered the wavelength range from 440 to 460 nm, with maxi-
mum emission at 455 nm (royal blue). One device, which
comprised 24 LEDs uniformly distributed throughout the
device giving a light intensity of 24 mW/cm2, was used to
illuminate the denture. This device was ﬁtted with three air
coolers to prevent the denture from being heated
[5,21,22]. The other device, designed to irradiate the
patient’s palate, comprised ten LEDs uniformly distributed
on a circular platform, with a power output of 260 mW
[5]. The intensity of light delivered was 102 mW/cm2, con-
sidering a distance of 2 cm from the platform inside the
mouth to the deepest area of the palate. Joined to this plat-
form, there was a semiconducting chip known as a Peltier,
used to dissipate the heat generated by the LED light. This
chip and an air cooler were used to prevent the device
from heating. To perform illumination, the platform remained
in the patient’s mouth with the LEDs facing toward the
palate.
Interventions
During the 3-month treatment and follow-up of each patient,
all subjects were instructed to brush their dentures with
coconut soap [24] followed by toothpaste, after every meal
and before going to sleep. They also received instructions to
immerse the dentures in ﬁltered water overnight. According
to the stratiﬁed randomization list, the patients were ran-
domly assigned to one of two treatment groups of 20 sub-
jects each. In the nystatin (NYT) group, patients were
submitted to topical antifungal treatment with nystatin oral
suspension 100 000 IU. Each patient received the medication
and was instructed to swish it for 1 min, gargle, and then
expectorate it four times daily for 15 days. In the PDT
group, each patient had his/her maxillary denture and palate
individually submitted to PDT as described previously [5].
Approximately 5 mL of photosensitizer was sprayed on the
inner and outer surfaces of each denture. After this, the den-
ture was placed in a transparent plastic bag and left in the
dark for 30 min (the pre-irradiation time). To perform illumi-
nation, the denture was placed inside the LED device and
irradiated for 26 min (37.5 J/cm2). The denture was centred
within the device and surrounded by LEDs during illumina-
tion. In this way, both the inner and outer denture surfaces
were illuminated. The palate was also sprayed with photo-
sensitizer and illuminated after 30 min of pre-irradiation
time. For palate irradiation, the other LED device was han-
dled by the investigator: the platform with LEDs was placed
in the patient’s mouth and the palate was illuminated for
20 min (122 J/cm2). PDT was performed three times a week
for 15 days (six sessions) in each patient.
Outcomes
The primary outcomes of interest were the Candida colony
counts from the palates and dentures surfaces, quantiﬁed as
CFU/mL, and severity of infection of the palatal mucosa, clas-
siﬁed according to the criteria proposed by Newton [23] (0,
absence of palatal inﬂammation; or Types I, II and III), mea-
sured before treatments (baseline), at the end of treatments
(day 15), and at follow-up (days 30, 60, and 90). The second
outcome was the prevalence of Candida spp. identiﬁed in the
two groups of treatments at the same time intervals.
Clinical and mycological procedures
For each patient of both groups, oral swab samples were
collected from the palatal mucosa and the tissue surface of
the maxillary denture as previously described [5]. Each swab
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FIG. 1. Absorption bands of Photogem and intensity of blue
(455 nm) LED light.
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was placed in a test tube containing 5 mL of 0.9% sterile sal-
ine and vortexed for 1 min to suspend the organisms from
the swab. Aliquots of 50 lL from this suspension were
spread plated on CHROMAgar Candida (Probac do Brasil
Produtos Bacteriolo´gicos Ltda., Sa˜o Paulo, SP, Brazil) and
incubated at 30C for 5 days. Serial ten-fold dilutions from
100 to 10)3 were plated onto Sabouraud Dextrose Agar
(SDA; Acumedia Manufacturers Inc., Baltimore, MD, USA)
with 5 mg/mL chloramphenicol. The SDA plates were incu-
bated at 37C for 48 h. Colonies on SDA were quantiﬁed
using a digital colony counter (CP 600 Plus; Phoenix Ind.
Com. Equipamentos Cientı´ﬁcos Ltda., Araraquara, SP, Brazil)
and the CFU/mL were determined. To document the clinical
response to treatment, standard photographs of the palate
of all patients were taken at these same time intervals (days
0, 15, 30, 60 and 90). All the photographs were taken with
the same digital camera (Sony Cyber-Shot DSC-F717; Sony
Corporation, Tokyo, Japan), by the same operator and under
the same conditions (place, light, angle and patient position)
to facilitate their reproducibility. Colonies on CHROMAgar
Candida were presumptively identiﬁed by colony colour and
submitted to biochemical tests to conﬁrm all identiﬁcations.
For this purpose, one colony of each colour type on CHRO-
MAgar Candida was transferred to fresh SDA for determina-
tion of purity. After 48 h at 37C, yeast isolates were
identiﬁed using the following biochemical tests: carbohydrate
assimilation pattern using the ID32C system (bioMe´rieux,
Marcy-l’Etoile, France) and morphological characteristics pro-
duced on corn meal agar with Tween-80. In addition, green
colonies on CHROMAgar Candida were submitted to a
hypertonic Sabouraud broth test for discriminating C. albicans
and C. dubliniensis [5]. All microbiological procedures were
carried out by the same operator.
Statistical analysis
The CFU/mL values were logarithm transformed to achieve a
normal distribution. However, unlike the data obtained from
palate, the distribution of the transformed data obtained from
dentures did not follow a normal distribution. Because the
patients were evaluated over time, a non-parametric test was
not considered appropriate to analyse these paired data so a
random-effects statistical model for longitudinal data was used.
With this model, data from dentures were transformed
(ln(CFU/mL))3/2 to ensure normality of residuals. The values
obtained from palates and dentures were analysed separately.
The factors ‘treatment group’ (NYT or PDT), and ‘time’ (days
0, 15, 30, 60 and 90) were submitted to analysis of variance
and p <0.05 taken as signiﬁcant. When differences were
found, Tukey’s post hoc test was implemented. Clinical signiﬁ-
cance between groups was determined by the effect size,
which was determined by taking the standardized mean differ-
ence in ln(CFU/mL) between pre-treatment and post-treat-
ment results for each group and dividing by the standard
deviation of the pre-treatment result. To interpret the result-
ing number, this general guide was used: <0.1 = trivial effect;
0.1–0.3 = small effect; 0.3–0.5 = moderate effect; and
>0.5 = large difference effect [25].
Fisher’s exact test was used to assess differences in the
degree of inﬂammation of the palate in relation to the pre-
disposing factors, and signiﬁcance was assumed when
p <0.05.
The standard photographs were evaluated by two inde-
pendent observers blinded to the treatment groups, period
of examination, risk factors and patients’ identity. These
observers were instructed to classify each photograph of the
palate as healthy or with DS type I, II or III. The j test was
used to assess the agreement between the observers and
p <0.05 was considered signiﬁcant.
Results
Patients and predisposing factors
Table 1 shows that in both groups the number of female
patients was higher than that of male patients, the mean age
of dentures was >10 years, most patients took medication
regularly, and few smokers participated. Before the study
began, a large percentage of patients wore their dentures at
night and at least 50% of the patients from the two groups
showed poor denture hygiene habits.
TABLE 1. Distribution of the predisposing factors (age and gender of the subjects, age of maxillary denture, medication use
and smoking) for both treatment groups
Group
Age of subjects
(years)
Gender of subjects
Age of dentures
(years)
Drugs
SmokingFemale Male AH Others None
NYT 41–78 (62.45) 15 5 2–47 (18.55) 9 15 5 2
PDT 43–80 (61.25) 13 7 1–44 (14) 9 14 6 4
AH, antihypertensive (most used drug); NYT, nystatin therapy; PDT, photodynamic therapy.
Mean values are given in parenthesis.
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On day 0, the distribution of patients with DS types I, II
and III in the NYT group was 20, 65 and 15%, respectively,
and for the PDT group it was 25, 50 and 25%, respectively.
The Fisher’s exact test showed that only the age of the den-
tures was signiﬁcantly associated with the severity of inﬂam-
mation of the palate (p 0.045). There was no signiﬁcant
association between the other predisposing factors (age, gen-
der, drugs and smoking) and the degree of inﬂammation.
Mycological efﬁcacy
Statistical analysis showed no signiﬁcant difference between
the CFU/mL values obtained from NYT and PDT groups dur-
ing all the time intervals of this study. After this, the CFU/mL
values from both groups were evaluated together at each
time of evaluation (days 0, 15, 30, 60 and 90). For dentures
and palates, a signiﬁcant reduction in ln(CFU/mL) mean values
was observed on days 15 and 30 compared with baseline (day
0) (Table 2). This reduction was higher on day 15 than on
day 30. At follow-up (days 30, 60 and 90), a signiﬁcant
increase in (ln(CFU/mL))3/2 mean values obtained from den-
tures was veriﬁed compared with the end of treatment (day
15). For palates, a signiﬁcant increase in ln(CFU/mL) mean
values was found only on day 60 of the follow-up period
when compared with the end of treatment (day 15). In
Table 2 it can also be observed that the effect size of treat-
ments was large for the palates of patients in the NYT group
(1.11) and moderate for the palates of patients in the PDT
group (0.39). For the dentures, the effect size was very large
for both groups (NYT group = 2.62; PDT group = 1.45).
At baseline (day 0), 97.5% of the swabs taken from the
entire ﬁtting surface of the dentures and 70% of the swabs
taken from the palatal mucosa produced yeast growth on
agar plates. Throughout this investigation, the CFU/mL val-
ues from the palates of patients from both groups were
lower than those from dentures and a large number of null
values were obtained from the palates. This could be attrib-
uted to the swab sampling method used for recovering Can-
dida cells.
Clinical efﬁcacy
Evaluation of the photographs showed high levels of agree-
ment (p <0.001) between the observers for every time of
examination: on day 0, j = 0.907 (standard error (SE) =
0.164); on day 15, j = 0.859 (SE = 0.120); on day 30,
j = 0.834 (SE = 0.118); on day 60, j = 0.852 (SE = 0.126);
and on day 90, j = 0.875 (SE = 0.126). These j coefﬁcients
are considered ‘almost perfect’, according to the recom-
mendations of Landis and Koch [26]. Once a high level of
inter-rater reliability was found, the percentage of patients
showing cure or improvement of the palatal inﬂammation
was determined. Clinical success (cure or improvement of
the palatal inﬂammation) was considered for each patient whose
degree of inﬂammation at the end of the treatment (day 15)
was absent or lower than it was at the baseline (day 0).
Hence, for the NYT group, 53% of the patients obtained
clinical success, while 41% and 6% showed no alteration and
worsening (failure of the treatment), respectively, of the pal-
atal inﬂammation. For the PDT group, 45% of the patients
achieved clinical success (Fig. 2a–c) and 55% showed no
TABLE 2. Mean values and standard deviation (in parenthesis) of Candida colony counts in ln(CFU/mL) from the palates and
dentures following treatments
Group Location
Period
Effect sizeDay 0 Day 15 Day 30 Day 60 Day 90
NYT Palate 4.51 (3.52) 0.61 (1.51)* 1.78 (3.32)* 2.77 (3.50) 2.15 (2.84) 1.11
Denture 30.88 (7.90) 10.19 (12.85)* 19.33 (15.79)*  21.41 (18.43) 19.84 (19.13)  2.62
PDT Palate 3.73 (2.95) 2.57 (3.33)* 3.02 (3.59)* 2.71 (3.45)  2.14 (3.48) 0.39
Denture 32.23 (12.86) 13.60 (14.64)* 28.09 (14.09)*  27.06 (14.25) 28.70 (14.70) 1.45
NYT, nystatin therapy; PDT, photodynamic therapy.
*Signiﬁcantly different from baseline (p <0.05); signiﬁcantly different from day 15 (p <0.05).
(a) (b)
(c) (d)
FIG. 2. Palate of patient from photodynamic therapy (PDT) group.
(a) Denture stomatitis (DS) type II (day 0); (b) no inﬂammation (day
15); (c) no inﬂammation (follow-up time interval, day 30); (d) DS
type I (follow-up time interval, day 60).
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alteration in the palatal inﬂammation. During the follow-up
(days 30, 60 and 90), recurrence of the palatal inﬂammation
was observed in 75% and 78% of the patients in the NYT
and PDT groups, respectively, who had previously obtained
clinical success (Fig. 2d).
Prevalence of Candida spp.
Candida albicans was the commonest species found on the
dentures and palates of patients during all the periods of this
investigation. Candida tropicalis was the next most common
yeast, followed by C. glabrata. Other species were observed
less frequently (Table 3). At the end of the treatment (day
15) it was veriﬁed that the number of isolates of C. albicans,
C. tropicalis and C. glabrata was reduced by 50%, 90% and
62.5%, respectively in the NYT group and 50%, 45.5% and
71.4%, respectively, in the PDT group compared with the
baseline (day 0) (Table 3). However, at the follow-up (days
30, 60 and 90) the number of these isolates increased com-
pared with the end of the treatments (day 15). On several
occasions, more than one species of yeast was isolated from
the dentures and palates (23.9% and 21.7% of swabs from
NYT and PDT groups, respectively). The combination of
C. albicans and C. tropicalis was the most prevalent of all yeast
mixtures in the NYT group (8.7%) and the second most pre-
valent in the PDT group (7.6%). Whereas, the association of
C. albicans and C. glabrata was the most prevalent in the PDT
group (8.6%) and the second most prevalent in the NYT
group (7.6%). The yeast mixture of C. albicans, C. tropicalis
and C. glabrata was detected in both groups (4.3% and 1.5%
in the NYT and PDT groups, respectively). Other yeast com-
binations were also found, but at lower rates. Mixed-species
populations were observed in 60% of the patients from the
NYT group and in 70% of the patients from the PDT group
on any day of evaluation, but more often at the baseline and
follow-up than at the end of the treatment (Table 4). When
compared with baseline (day 0), reductions of 50% and 54%
in the mixed species were veriﬁed at the end of treatments
(day 15) for NYT and PDT groups, respectively.
Discussion
The present investigation compared the clinical and microbi-
ological efﬁcacy of PDT with that of conventional antifungal
therapy in patients with DS. The microbiological results
showed no signiﬁcant difference between PDT and conven-
tional antifungal therapy in the inactivation of Candida spp. At
the end of both treatments (day 15), a signiﬁcant reduction
in CFU/mL recovered from dentures and palate was found in
comparison with baseline (day 0). This result is in agreement
with a previous case report in which reduction of CFU/mL
of ﬁve patients with DS was observed after six sessions of
PDT [5]. Interestingly, on day 30 of the follow-up period
(15 days after the end of both treatments), the mean values
of CFU/mL were still signiﬁcantly lower than those at base-
line. This could be explained by the patients’ compliance with
denture and oral hygiene advice given during this research.
Although not sufﬁcient to treat DS [24,25], denture and oral
TABLE 3. Number of isolates of each species found on dentures and palates of patients in the NYT and PDT groups on each
day of evaluation
Species
Day 0 Day 15 Day 30 Day 60 Day 90 Total
NYT PDT NYT PDT NYT PDT NYT PDT NYT PDT NYT PDT
Candida albicans 36 26 18 13 21 22 25 18 19 20 119 (63.3) 99 (54)
C. tropicalis 10 11 1 6 5 5 6 8 6 8 28 (15) 38 (21)
C. glabrata 8 7 3 2 6 4 6 5 4 4 27 (14.4) 22 (12)
C. lusitaniae 2 0 0 0 0 0 0 2 0 0 2 (1) 2 (1)
C. parapsilosis 3 0 0 0 1 0 0 0 0 0 4 (2) 0
C. rugosa 0 1 0 1 0 0 0 0 0 1 0 3 (1.6)
C. guillermondii 0 0 2 0 0 0 0 1 0 0 2 (1) 1 (0.5)
Cryptococcus humicola 0 4 3 3 1 3 1 4 0 3 5 (2.7) 17 (9)
Rhodotorula glutinis 0 0 0 0 0 0 1 0 0 0 1 (0.5) 0
Cryptococcus albidus 0 1 0 0 0 0 0 0 0 0 0 1 (0.5)
Kloeckera apis/apiculata 0 0 0 1 0 0 0 0 0 0 0 1 (0.5)
NYT, nystatin therapy; PDT, photodynamic therapy.
Percentage values are given in parenthesis.
TABLE 4. Number of isolates of mixed-species populations
found on dentures and palates of patients in the NYT and
PDT groups at the baseline (day 0), at the end of the treat-
ments (day 15) and at the follow-up (days 30, 60 and 90)
Group
Days
0 15 30 60 90
NYT 14 (28.6) 7 (14.3) 10 (20.4) 10 (20.4) 8 (16.3)
PDT 13 (30.2) 6 (14) 5 (11.6) 12 (27.9) 7 (16.3)
NYT, nystatin therapy; PDT, photodynamic therapy.
Percentage values are given in parenthesis.
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hygiene are essential to maintain a low level of microorgan-
isms on dentures, as well as oral health.
Although several in vitro investigations have conﬁrmed the
potential of PDT to inactivate Candida spp. [14–16,18–22],
this is the ﬁrst clinical trial to evaluate the effect of PDT on
the treatment of Candida infection. Although Teichert et al.
[20] stated that mice with oral candidiasis were treated using
PDT, they only observed a dose-dependent eradication of
C. albicans from the oral cavity using methylene blue and
laser irradiation. However, the regression of lesions, which is
an important clinical sign of treatment, was not evaluated by
these authors. Furthermore, the association of Photogem
with LED light showed a signiﬁcant reduction in the CFU/mL
of C. albicans recovered from the tongues of mice with oral
candidiasis and no adverse effects were observed on the tis-
sues of the tongue [16]. Nevertheless, complete eradication
of yeast was not achieved. A previous in vivo study also
showed that PDT, using approximately the same parameters
as this investigation, was not toxic to the rat palatal mucosa
when 500 mg/L of Photogem was associated with 144 J/cm2
of blue LED light [17]. Hence, potential toxic or adverse
effects of PDT on palatal tissue may seem unlikely. In fact, it
is difﬁcult to compare the results of this clinical trial with
those of in vitro studies and animal models because the oral
environment of humans is different, and factors such as mic-
robiota and bioﬁlm composition, salivary ﬂux, oral hygiene
and food habits might inﬂuence the response to PDT. None-
theless, the outcome of the present investigation suggests
that PDT may be an alternative method for inactivation of
Candida spp. in patients with DS.
During the follow-up period (days 30, 60 and 90), the
mean values of CFU/mL recovered from dentures were sig-
niﬁcantly higher than those found at the end of the treat-
ment (day 15). This result was expected because progressive
recolonization of dentures starts after the end of the treat-
ment. On the other hand, only on day 60 of the follow-up
period was the mean value of CFU/mL recovered from the
palate signiﬁcantly higher than that at the end of treatment
(day 15). The results obtained during the follow-up period
may be explained by the high afﬁnity of Candida spp. to
adhere to and colonize acrylic surfaces. Virulence factors of
Candida spp., such as cell-surface hydrophobicity [27] and
ability to form bioﬁlm [10], increase its adherence to acrylic
surfaces. Other investigations have also demonstrated that
Candida spp. are primarily found on the tissue surface of the
denture rather than on the palatal mucosa of patients with
or without DS [5,25,28]. This result corroborates that of the
present study, because the palatal cultures evidenced lower
CFU/mL mean values than the denture cultures for all the
time intervals evaluated. The low level of CFU/mL recovered
can be partially attributed to the sample technique (swab
sampling) employed in the present investigation. An in vitro
study showed that C. albicans was able to invade a reconsti-
tuted human oral epithelium over a period of 48 h through
hyphal penetration into the superﬁcial epithelium together
with features of cellular internalization of yeasts [29]. There-
fore, a delicate cotton swab used in this study for recovering
yeast may underestimate the real burden of Candida spp.
present on the palatal mucosa and denture surface. Hence,
another sampling technique, such as an oral rinse method
using saline or sterile water, would have been valuable to
monitor the overall Candida burden in the oral cavity of the
patients at baseline and at subsequent evaluations.
In the present study, a higher percentage of clinical success
was veriﬁed in the NYT group (53%) than in the PDT group
(45%). Nystatin would have also reduced Candida cells on the
tongue and buccal mucosa in patients from the NYT group,
which could justify the higher percentage of success in this
group. On the other hand, no antimicrobial treatment of the
dentures was performed in this group, which could have con-
tributed to the rate of clinical failure obtained (47%). The high
rate of clinical failure observed in the PDT group (55%) might
be attributed to the recolonization of the palatal mucosa after
PDT by Candida cells from other sites of the mouth, such as
tongue, particularly mid-dorsum, and buccal mucosa. In addi-
tion, the clinical conditions in which PDT was performed,
such as treatment time (three times a week for 15 days, a
total of six sessions) and the parameters used (only one type
and concentration of photosensitizer and light ﬂuence) might
also explain the rate of clinical failure observed in this group.
A longer treatment period might achieve a better resolution
of palatal inﬂammation. Further trials are necessary to
evaluate the effect of additional parameters of PDT, such as
other types and concentrations of photosensitizer and light
ﬂuences, in an endeavour to ﬁnd a higher clinical success rate.
In the present investigation, the clinical failure rates are not
in agreement with the microbiological results obtained, i.e. a
reduction in CFU/mL values was observed even in patients
who showed no improvement in palatal inﬂammation. This cor-
roborates the ﬁndings of Barbeau et al. [1], and Zomorodian
et al. [8] who found no signiﬁcant relationship between DS and
number of yeast colonies. Furthermore, other reports have
demonstrated that healthy denture wearers were also Candida
carriers [3,6,22,28]. Although both treatments resulted in a sig-
niﬁcant reduction in values of CFU/mL from dentures and pal-
ates in this study, and given that the aetiology of DS is
multifactorial, a more effective treatment should be directed
towards all aetiological factors involved in this pathology.
This investigation demonstrated that among the patients
who showed clinical success, a high rate of recurrence was
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found in the follow-up period (75% for NYT group and 78%
for PDT group). Recurrence of infection after the conclusion
of treatment has often been reported [4,5,12], because the
tissue surface of the acrylic resin denture acts as a reservoir
that harbours microorganisms, and is therefore, a potential
source of re-infection of patients. Replacement of dentures
is also necessary for complete resolution of DS [6], espe-
cially when dentures are very old. The present study also
showed that the age of dentures was the only predisposing
factor signiﬁcantly associated with the degree of inﬂammation
of the palate. The age of maxillary denture of 52.5% of
patients was over 12 years, which could have contributed to
the proliferation of yeasts on denture surfaces at follow-up.
This result is in agreement with that of Neppelenbroek et al.
[25], Zomorodian et al. [8] and Figueiral et al. [2], who found
that the time of denture use was related to DS. From this
standpoint, the provision of new dentures should also be
considered during the management of DS.
The outcomes of the present study showed that C. albicans
was the predominant species isolated from the dentures and
palates of patients from the NYT and PDT groups (63.3% and
54%, respectively). This ﬁnding is in agreement with previous
reports [2,3,6–8,22,28]. The next most common species found
was C. tropicalis followed by C. glabrata in both groups. Investi-
gations have also observed that C. tropicalis was the second
most prevalent species isolated from the oral cavity [6,7].
However, other studies have found that C. glabrata was the
most common yeast after C. albicans [2–4,8,22,28]. The pres-
ence of non-C. albicans species is a cause for concern because
they are able to cause infection and are frequently resistant to
antifungal agents. In the present study, considerable rates of
reduction in the number of isolates of C. albicans, C. tropicalis
and C. glabrata, as well as other yeasts species, were veriﬁed at
the end of the treatments. This result demonstrated that these
species were susceptible to nystatin and PDT, except C. tropi-
calis, which showed higher susceptibility to nystatin (90% of
reduction) than PDT (45.5% of reduction). Nonetheless, the
increased number of these isolates observed in the follow-up
period when compared with the end of the treatments may be
attributed to recolonization of the mucosa and denture.
During all the time intervals of this investigation, 60% and
70% of the patients from NYT and PDT groups showed
mixed-species populations. In other studies, more than one
yeast species was found in 27.27% [3], 14.4% [7] and 48.5%
[28] of subjects without DS, and 38.5% [3] and 32.5% [7] of
individuals with DS. The complex interactions among yeasts
in synergistic relationships are not well known, but may be
involved in the enhanced pathogenic potential of these asso-
ciations. In this investigation, mixed-species were reduced by
50% and 54% in the NYT and PDT groups, respectively, at
the end of the treatments. This suggests that both treat-
ments were effective in reducing more complex bioﬁlms.
In conclusion, despite the limitations of this ﬁrst clinical
investigation, such as the low number of patients evaluated,
the results demonstrated that PDT was as effective as topical
nystatin in reducing the CFU/mL of Candida spp. from the
dentures and palates of patients with DS, but a higher num-
ber of patients showed decrease in palatal inﬂammation after
nystatin. In addition, a high rate of recurrence was observed,
and C. albicans was the most prevalent species identiﬁed. Fur-
ther studies are required to determine more effective clinical
parameters for a better response to PDT in patients with
DS, and more patients should be assessed to draw ﬁrmer
conclusions. The principal advantage of PDT is that, unlike
antifungal agents, development of resistance to phototherapy
seems to be improbable because of its mechanism of action,
and potential toxic or adverse effects of PDT on palatal tis-
sue are unlikely. Moreover, according to the results of this
investigation, fewer sessions of PDT are necessary to achieve
the same clinical outcome as nystatin, which, on the other
hand, requires multiple daily doses, which can lower the
patient’s compliance. As PDT is performed in the dental
ofﬁce, dentists can also monitor the therapeutic sessions and
the patient’s response gradually. Therefore, PDT seems to
be a promising method for the treatment of DS.
Acknowledgements
These data were presented in part at the 88th General Ses-
sion and Exhibition of the International Association of Dental
Research (IADR), Barcelona, Spain (#1787) and the 89th
General Session and Exhibition of the IADR, San Diego, CA,
USA (#3494).
Transparency Declaration
This work was supported by FAPESP—Sa˜o Paulo Research
Council (Grant no 2005/02193-4, 2005/03226-3 and 2010/
01212-3), and CePOF—CEPID Program (Center for Research
in Optics and Photonics—Center for Research, Innovation
and Diffusion). No conﬂict of interest to be declared.
References
1. Barbeau J, Se´guin J, Goulet JP et al. Reassessing the presence of Can-
dida albicans in denture-related stomatitis. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod 2003; 95: 51–59.
CMI Mima et al. PDT · nystatin for denture stomatitis E387
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E380–E388
2. Figueiral MH, Azul A, Pinto E, Fonseca PA, Branco FM, Scully C. Den-
ture-related stomatitis: identiﬁcation of aetiological and predisposing
factors – a large cohort. J Oral Rehabil 2007; 34: 448–455.
3. Coco BJ, Bagg J, Cross LJ, Jose A, Cross J, Ramage G. Mixed Candida
albicans and Candida glabrata populations associated with the patho-
genesis of denture stomatitis. Oral Microbiol Immunol 2008; 23:
377–383.
4. Cross LJ, Williams DW, Sweeney CP, Jackson MS, Lewis MA, Bagg
J. Evaluation of the recurrence of denture stomatitis and Candida
colonization in a small group of patients who received itraconaz-
ole. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97:
351–358.
5. Mima EG, Pavarina AC, Silva MM et al. Denture stomatitis treated
with photodynamic therapy: ﬁve cases. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod 2011; 112: 602–608.
6. Pires FR, Santos EB, Bonan PR, De Almeida OP, Lopes MA. Denture
stomatitis and salivary Candida in Brazilian edentulous patients. J Oral
Rehabil 2002; 29: 1115–1119.
7. Sanita´ PV, Pavarina AC, Giampaolo ET et al. Candida spp. prevalence
in well controlled type 2 diabetic patients with denture stomatitis.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111: 726–
733.
8. Zomorodian K, Haghighi NN, Rajaee N et al. Assessment of Candida
species colonization and denture-related stomatitis in complete den-
ture wearers. Med Mycol 2011; 49: 208–211.
9. Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing
fungal development, drug resistance, and disease. Microbiol Mol Biol
Rev 2011; 75: 213–267.
10. Chandra J, Mukherjee PK, Leidich SD et al. Antifungal resistance of
candidal bioﬁlms formed on denture acrylic in vitro. J Dent Res 2001;
80: 903–908.
11. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin
Infect Dis 2002; 35: 1073–1080.
12. Banting DW, Greenhorn PA, McMinn JG. Effectiveness of a topical
antifungal regimen for the treatment of oral candidiasis in older,
chronically ill, institutionalized, adults. J Can Dent Assoc 1995; 61:
199–200, 203–205.
13. Pallasch TJ. Antifungal and antiviral chemotherapy. Periodontol 2000
2002; 28: 240–255.
14. Donnelly RF, McCarron PA, Tunney MM. Antifungal photodynamic
therapy. Microbiol Res 2008; 163: 1–12.
15. Konopka K, Goslinski T. Photodynamic therapy in dentistry. J Dent
Res 2007; 86: 694–707. Erratum in: J Dent Res 86: 1126.
16. Mima EG, Pavarina AC, Dovigo LN et al. Susceptibility of Candida
albicans to photodynamic therapy in a murine model of oral candido-
sis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:
392–401.
17. Trindade FZ, Pavarina AC, Ribeiro AP, Bagnato VS, Vergani CE,
Costa CA. Toxicity of photodynamic therapy with LED associated to
Photogem: an in vivo study. Lasers Med Sci 2012; 27: 403–411.
18. Donnelly RF, McCarron PA, Tunney MM, David Woolfson A. Poten-
tial of photodynamic therapy in treatment of fungal infections of the
mouth design and characterisation of a mucoadhesive patch contain-
ing toluidine blue O. J Photochem Photobiol, B 2007; 86: 59–69.
19. Dovigo LN, Pavarina AC, Mima EG, Giampaolo ET, Vergani CE, Bag-
nato VS. Fungicidal effect of photodynamic therapy against ﬂuconaz-
ole-resistant Candida albicans and Candida glabrata. Mycoses 2011; 54:
123–130.
20. Teichert MC, Jones JW, Usacheva MN, Biel MA. Treatment of oral
candidiasis with methylene blue-mediated photodynamic therapy in
an immunodeﬁcient murine model. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod 2002; 93: 155–160.
21. Mima EG, Pavarina AC, Ribeiro DG, Dovigo LN, Vergani CE, Bagnato
VS. Effectiveness of photodynamic therapy for the inactivation of Can-
dida spp. on dentures: in vitro study. Photomed Laser Surg 2011; 29:
827–833.
22. Ribeiro DG, Pavarina AC, Dovigo LN et al. Photodynamic inactivation
of microorganisms present on complete dentures a clinical investiga-
tion: photodynamic disinfection of complete dentures. Lasers Med Sci
2012; 27: 161–168.
23. Newton AV. Denture sore mouth as possible aetiology. Br Dent J
1962; 112: 357–360.
24. Barnabe´ W, de Mendonc¸a Neto T, Pimenta FC, Pegoraro LF, Scolaro
JM. Efﬁcacy of sodium hypochlorite and coconut soap used as disin-
fecting agents in the reduction of denture stomatitis, Streptococcus
mutans and Candida albicans. J Oral Rehabil 2004; 31: 453–459.
25. Neppelenbroek KH, Pavarina AC, Palomari Spolidorio DM, Sgavioli
Massucato EM, Spolidorio LC, Vergani CE. Effectiveness of micro-
wave disinfection of complete dentures on the treatment of Candida-
related denture stomatitis. J Oral Rehabil 2008; 35: 836–846.
26. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics 1977; 33: 159–174.
27. Klotz SA, Drutz DJ, Zajic JE. Factors governing adherence of Candida
species to plastic surfaces. Infect Immun 1985; 50: 97–101.
28. Vanden Abbeele A, de Meel H, Ahariz M, Perraudin JP, Beyer I,
Courtois P. Denture contamination by yeasts in the elderly. Gerodon-
tology 2008; 25: 222–228.
29. Jayatilake JA, Samaranayake YH, Samaranayake LP. An ultrastructural
and a cytochemical study of candidal invasion of reconstituted human
oral epithelium. J Oral Pathol Med 2005; 34: 240–246.
E388 Clinical Microbiology and Infection, Volume 18 Number 10, October 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E380–E388
